XML 89 R32.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract] |
Summary of Assets and Liabilities Held For Sale | The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following:
|  | As of December 31,
(MILLIONS OF DOLLARS) |  | 2018 |  |  | 2017 |
Assets Held for Sale |  |  |  |
Cash and cash equivalents |  | $ | 32 |  |  | $ | — |
Trade accounts receivable, less allowance for doubtful accounts |  | 532 |  |  | — |
Inventories |  | 538 |  |  | — |
Other current assets |  | 56 |  |  | — |
PP&E |  | 675 |  |  | — |
Identifiable intangible assets, less accumulated amortization |  | 5,763 |  |  | — |
Goodwill |  | 1,972 |  |  | — |
Noncurrent deferred tax assets and other noncurrent tax assets |  | 54 |  |  | — |
Other noncurrent assets |  | 57 |  |  | — |
Total Consumer assets held for sale |  | 9,678 |  |  | — |
Other assets held for sale(a) |  | 46 |  |  | 12 |
Assets held for sale |  | $ | 9,725 |  |  | $ | 12 |
Liabilities Held for Sale |  |  |  |
Trade accounts payable |  | $ | 406 |  |  | $ | — |
Income taxes payable |  | 39 |  |  | — |
Accrued compensation and related items |  | 93 |  |  | — |
Other current liabilities |  | 353 |  |  | — |
Pension benefit obligations, net |  | 39 |  |  | — |
Postretirement benefit obligations, net |  | 33 |  |  | — |
Noncurrent deferred tax liabilities |  | 870 |  |  | — |
Other noncurrent liabilities |  | 56 |  |  | — |
Total Consumer liabilities held for sale |  | $ | 1,890 |  |  | $ | — |
(a) | Other assets held for sale consist of PP&E.
Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions |
The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:
|  | Year Ended December 31,
(MILLIONS OF DOLLARS) |  | 2018 |  |  | 2017 |  |  | 2016 |
Revenues—Revenues(a) |  | $ | 571 |  |  | $ | 606 |  |  | $ | 659 |
Revenue s—Alliance revenues(b) |  | 3,838 |  |  | 2,927 |  |  | 1,746 |
Total revenues from collaborative arrangements |  | 4,409 |  |  | 3,533 |  |  | 2,405 |
Cost of sales(c) |  | (296 | ) |  | (329 | ) |  | (315 | )
Selling, informational and administrative expenses(d) |  | (90 | ) |  | (54 | ) |  | (5 | )
Research and development expenses(e) |  | 162 |  |  | 222 |  |  | 64 |
Other income/(deductions)—net(f) |  | 281 |  |  | 249 |  |  | 542 |
(a) | Represents sales to our partners of products manufactured by us.
(b) | Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in 2018 and 2017 reflect increases in alliance revenues from Eliquis and Xtandi.
(c) | Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.
(d) | Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.
(e) | Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: $50 million in 2018, $15 million in 2017 and $15 million in 2016. Our collaboration with Lilly (see below) also includes reimbursements of $98 million in 2018, $147 million in 2017 and $120 million in 2016.
(f) | Primarily relates to royalties from our collaboration partners. The decrease in 2017 is due to the October 31, 2016 expiration of our 36 month royalty arrangement on sales of Enbrel in the U.S. and Canada, partially offset by a full year of royalties earned in 2017, versus a partial year in 2016, on Xtandi ex-U.S. sales.

X
- Definition Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract] + References No definition available. + Details
Name: | pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract
Namespace Prefix: | pfe_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3A -URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5D -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3A -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 4B -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760 Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5C -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760 Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5A -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760 Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 5B -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760 Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 4A -URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760 + Details
Name: | us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration